Discontinued — last reported Q3 '23
Eli Lilly Acquisitions increased by 848.0% to $1.06B in Q1 2026 compared to the prior quarter.
High spending indicates an aggressive growth or diversification strategy, while low spending suggests a focus on organic growth or internal consolidation.
This metric tracks the cash paid to acquire other businesses or business units, net of any cash acquired in the transact...
Varies significantly based on M&A cycles; peers in the healthcare sector frequently use acquisitions to gain access to new diagnostic or therapeutic technologies.
acquisitions| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $327.20M | $0.00 | $1.04B | $300.00K | $0.00 | $0.00 | $549.40M | $111.60M | $1.06B |
| QoQ Change | — | — | — | — | -100.0% | — | -100.0% | -100.0% | — | — | -79.7% | +848.0% |
| YoY Change | — | — | — | — | — | +219.1% | -100.0% | — | — | — | >999% | — |